This company has been acquired
Dividendos de TCR2 Therapeutics
Dividendo controles de criterios 0/6
TCR2 Therapeutics does not have a record of paying a dividend.
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
Rentabilidad media de la industria | 2.9% |
Próxima fecha de pago de dividendos | n/a |
Fecha ex dividendo | n/a |
Dividendo por acción | n/a |
Beneficios por acción | -US$4.15 |
Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
No hay actualizaciones
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if TCRR's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
Rentabilidad por dividendo de TCR2 Therapeutics vs. Mercado |
---|
Segmento | Rentabilidad por dividendo |
---|---|
Empresa (TCRR) | n/a |
Suelo de mercado 25% (US) | 1.5% |
Techo de mercado 25% (US) | 4.7% |
Media de la industria (Biotechs) | 2.9% |
Previsión de analistas en 3 años (TCRR) | n/a |
Dividendo destacado: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Alto dividendo: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Pago de beneficios a los accionistas
Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as TCRR has not reported any payouts.